Table 2 Relationship between expression levels of WT1 and clinical and pathological features of the NSCLC individuals
Clinical Characteristics | Non-increased (ΔΔCt ≤ 1) n = 27 | Increased (ΔΔCt > 1) n = 33 | Test of Significance |
|---|---|---|---|
Sex | |||
Female | 9 (15.00%) | 12 (20.00%) | χ2 = 0.0599 |
Male | 18 (30.00%) | 21 (35.00%) | P = 0.8066 |
Age | |||
< 60 | 15 (25.00%) | 21 (35.00%) | χ2 = 0.4040 |
>=60 | 12 (20.00%) | 12 (20.00%) | P = 0.5250 |
Tumour Type | |||
Squamous cell lung carcinoma | 11 (18.33%) | 14 (23.33%) | |
Lung adenocarcinoma | 16 (26.67%) | 17 (28.33%) | χ2 = 1.8084 |
Others | 0 (0.00%) | 2 (3.33%) | P = 0.5825 F |
T Stage | |||
T1 | 18 (30.00%) | 9 (15.00%) | χ2 = 9.3113 |
T2 + T3 | 9 (15.00%) | 24 (40.00%) | P = 0.0023 |
N Stage | |||
N0 | 18 (30.00%) | 13 (21.67%) | χ2 = 4.4231 |
N1 + N2 | 9 (15.00%) | 20 (33.33%) | P = 0.0355 |
Tumour Grade | |||
I + II | 22 (36.67%) | 17 (28.33%) | χ2 = 5.8615 |
III + IV | 5 (8.33%) | 16 (26.67%) | P = 0.0155 |
Differentiation | |||
Well | 6 (10.00%) | 8 (13.33%) | |
Moderate | 14 (23.33%) | 19 (31.67%) | χ2 = 0.5255 |
Poor | 7 (11.67%) | 6 (10.00%) | P = 0.7689 |